HALIFAX, April 3 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR,
NASDAQ: MMIRF) a global market leader in premium rapid diagnostic solutions,
announced today that it has received a second order for its MiraWell Rapid HIV
Tests from its Colombian distributor, CI Grupo Vargas Bueno & Cia S.A. This
order for 40,000 units is double the initial order from this distributor.
The tests will be sold to hospitals and clinical laboratories in
Colombia, and CI Grupo Vargas Bueno & Cia S.A. will also be participating in
government tenders for national testing programs and public health
initiatives. According to the latest data from UNAIDS, released in May 2006,
there are currently 160,000 people in Colombia living with HIV/AIDS.
"We're pleased to receive this follow-up order from Colombia with such an
increase in volume. This clearly demonstrates that rapid testing is taking
hold in this market," said Hermes Chan, President & CEO, MedMira. "We will
continue to support and work with our distributor to build on the
opportunities in this market, as demand for quality rapid testing increases in
all sectors of the diagnostics market in Colombia."
The MiraWell HIV test delivers results instantly and is designed for use
in all types of testing environments and programs, including occupational
exposures, labor & delivery, emergency departments, and large scale public
health testing programs. It is built on MedMira's core technology, the basis
for all MedMira's rapid HIV tests, which have achieved gold standards in
regulatory approvals around the world, including Health Canada, US FDA, China
SFDA, and the European Union CE Mark.
MedMira is a leading developer and manufacturer of flow-through rapid
diagnostics. The company's tests provide hospitals, labs, clinics and
individuals around the world with reliable, rapid diagnosis for diseases such
as HIV and hepatitis C in just three minutes. The company's tests are sold
under the Reveal(R), MiraWell(R), MiraCare(TM) and Multiplo(TM) brands in
global markets. MedMira's rapid HIV test is the only one in the world to
achieve regulatory approvals in Canada, the United States, China and the
The company's corporate offices and manufacturing facilities are located
in Halifax, Nova Scotia, Canada with a representative office in China. For
more information visit MedMira's website at www.medmira.com.
This news release contains forward-looking statements, which involve risk
and uncertainties and reflect the company's current expectation regarding
future events. Actual events could materially differ from those projected
herein and depend on a number of factors including, but not limited to,
changing market conditions, successful and timely completion of clinical
studies, uncertainties related to the regulatory approval process,
establishment of corporate alliances and other risks detailed from time to
time in the company quarterly filings.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this statement.
For further information:
For further information: Dr. James Smith, Investor Relations, (902)